Free Trial

Foghorn Therapeutics (FHTX) SEC Filings & 10K Form

$6.76
+0.24 (+3.68%)
(As of 07/26/2024 ET)

Recent Foghorn Therapeutics SEC Filings

DateFilerForm TypeView
06/26/2024
3:04 PM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2024
8:48 AM
FMR LLC (Filed by)
Foghorn Therapeutics (Subject)
Form SC 13G/A
05/23/2024
6:03 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/20/2024
3:31 PM
Foghorn Therapeutics (Filer)
Form 424B5
05/20/2024
7:02 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2024
3:54 PM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2024
6:03 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2024
6:03 AM
Foghorn Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/06/2024
6:03 AM
Foghorn Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/03/2024
7:00 AM
Foghorn Therapeutics (Filer)
Form DEF 14A
05/03/2024
7:01 AM
Foghorn Therapeutics (Filer)
Form DEFA14A
05/03/2024
7:03 AM
Foghorn Therapeutics (Filer)
Form ARS
04/16/2024
6:01 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/09/2024
3:41 PM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/12/2024
3:19 PM
Cavalie Fanny (Reporting)
Foghorn Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
6:09 AM
Foghorn Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/07/2024
6:11 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/08/2024
6:04 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2024
6:04 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/02/2023
6:03 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/02/2023
6:08 AM
Foghorn Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/08/2023
6:04 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/31/2023
6:04 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/16/2023
3:33 PM
Agresta Samuel (Reporting)
Foghorn Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/08/2023
6:05 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/04/2023
6:05 AM
Foghorn Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/04/2023
6:08 AM
Foghorn Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:FHTX) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners